Combined hormone therapy linked to worsening headaches
Among women with migraine histories, combined therapy was linked to 1.53 times the risk of worsening headaches over one year compared with placebo.
Our read
Interventions- Studied:
- Randomized trial in 22,876 postmenopausal women, 1-year follow-up, against placebo (Placebo-controlled)
- What changed:
- Headaches worsened more often with combined hormone therapy than placebo (adjusted risk ratio 1.18)
- The catch:
- The four-point headache scale could miss subtle changes in participants with consistently severe headaches
- In the record:
- The 146th paper on estrogen with results in people; 541 on record in all.
Editor of record: Boris Djordjevic · AgingResearch.News
The 22,876 postmenopausal women in this secondary analysis of two parallel randomized, placebo-controlled trials averaged 64 years old and lived in the United States. Women with a uterus were assigned daily pills containing 0.625 mg conjugated equine estrogens and 2.5 mg medroxyprogesterone acetate (a progestin, or progesterone-like hormone), or placebo. Those whose uterus had been removed were assigned estrogen alone or placebo. Participants rated headache severity at enrollment and one year.
Estrogen alone was not linked to worsening headaches in either migraine-history group. Combined therapy was linked to worsening headaches in both groups. Among women with migraine histories, its link to greater headache severity was uncertain: the range of likely values included no difference.
Why it matters
Headache symptoms after menopause are part of the broader question of hormone therapy’s risks and benefits as women age.
Caveats
The authors note that questionnaires could not distinguish headache types, so the findings concern headaches generally, not migraine specifically. They caution against extending the results to other hormone regimens or to women before or during menopause.
From the paper
- Participants
Briefly, the WHI-HT began in 1993 and enrolled 27,347 postmenopausal individuals between the ages of 50 and 79 years at 40 WHI clinical centers across the United States, 24,619 of whom had complete data on migraine status at baseline.
- Events by group
Across migraine history and treatment groups, 17.6%–27.7% of participants reported an improvement in their headaches, 48.5%–68.7% reported their headaches remained the same, and 14.1%–25.6% reported their headaches worsened.
- Limitation
Our study was limited to the specific MHT regimens and doses tested in the WHI, limiting generalizability to the other existing formulations, doses, and routes of estrogen and progestogens.
Quoted word for word from the full text on PubMed Central.
The paper
Brigham and Women's Hospital; Stanford Medicine
Headache, Jul 8, 2026, Open access, accepted manuscript
Comments
Be the first to comment.